Dermatology Space Waits For Skinny On Stiefel Buyout
This article was originally published in The Pink Sheet Daily
Executive Summary
Pure dermatology plays abound, but few are big enough to take on privately held Stiefel; where the company will find a fit is anybody’s guess.
You may also be interested in...
GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal
Acquisition more than doubles GSK’s dermatology sales to $1.5 billion, creating a global specialist business across prescription and OTC drugs.
GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal
Acquisition more than doubles GSK’s dermatology sales to $1.5 billion, creating a global specialist business across prescription and OTC drugs.
PPD Buys Into Dermatology, Peels Off Cancer
Takeover of Magen for $14.5M adds early-stage compounds licensed from Lilly last year.